JFL Capital Ends Campaign at Merrimack

Wednesday, September 25, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Pleased Involvement Catalyzed Much Needed Change at Merrimack and Intends to Continue to Monitor Situation

LAKEWAY, Texas, Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its affiliates, "JFL Capital"),

the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximately 9.4% of the Company's outstanding shares, announced today that it has withdrawn its solicitation in connection with the Company's 2019 annual meeting of stockholders (the "Annual Meeting").

In response to JFL Capital initiating its campaign for change at Merrimack, the Company has undergone significant changes, including multiple cash distributions and most recently appointing two stockholder representative to its Board of Directors (the "Board").  We hope the newly appointed Board members will focus on cost containment, continued NOL safeguarding, and milestone payment and stockholder distribution maximization. JFL Capital is pleased to have served as the catalyst for these much needed changes, and, as a result, has determined to withdraw its slate of nominees for election at the Annual Meeting.

JFL Capital is hopeful that the newly appointed stockholder representatives on the Board will ensure that future payments from Ipsen and 14ner Oncology are distributed to stockholders in their entirety. It is the Board's responsibility to ensure an orderly and cost effective liquidation.

JFL Capital intends to monitor the situation closely and encourages the Board to consider further cost savings such that more cash can be returned to the Company's stockholders.

Contacts:Joseph F. Lawler M.D., Ph.D.(512) 761-4500

Cision View original content:http://www.prnewswire.com/news-releases/jfl-capital-ends-campaign-at-merrimack-300924657.html

SOURCE JFL Capital Management, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store